Omer Rabia, Mohsin Muhammad Zubair, Mohsin Ali, Mushtaq Bilal Sajid, Huang Xumeng, Guo Meijin, Zhuang Yingping, Huang Jiaofang
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
State Key Laboratory of Food Science and Technology, School of Food Science and Technology, National Engineering Research Center for Functional Food, Jiangnan University, Wuxi, China.
Front Bioeng Biotechnol. 2022 Apr 28;10:870675. doi: 10.3389/fbioe.2022.870675. eCollection 2022.
Future advances in therapeutics demand the development of dynamic and intelligent living materials. The past static monofunctional materials shall be unable to meet the requirements of future medical development. Also, the demand for precision medicine has increased with the progressively developing human society. Therefore, engineered living materials (ELMs) are vitally important for biotherapeutic applications. These ELMs can be cells, microbes, biofilms, and spores, representing a new platform for treating intractable diseases. Synthetic biology plays a crucial role in the engineering of these living entities. Hence, in this review, the role of synthetic biology in designing and creating genetically engineered novel living materials, particularly bacteria, has been briefly summarized for diagnostic and targeted delivery. The main focus is to provide knowledge about the recent advances in engineered bacterial-based therapies, especially in the treatment of cancer, inflammatory bowel diseases, and infection. Microorganisms, particularly probiotics, have been engineered for synthetic living therapies. Furthermore, these programmable bacteria are designed to sense input signals and respond to disease-changing environments with multipronged therapeutic outputs. These ELMs will open a new path for the synthesis of regenerative medicines as they release therapeutics that provide drug delivery with lower systemic effects. In last, the challenges being faced in this field and the future directions requiring breakthroughs have been discussed. Conclusively, the intent is to present the recent advances in research and biomedical applications of engineered bacteria-based therapies during the last 5 years, as a novel treatment for uncontrollable diseases.
治疗学的未来进展需要开发动态和智能的生物材料。过去的静态单功能材料将无法满足未来医学发展的需求。此外,随着人类社会的不断发展,对精准医学的需求也在增加。因此,工程化生物材料(ELMs)在生物治疗应用中至关重要。这些ELMs可以是细胞、微生物、生物膜和孢子,代表了一种治疗难治性疾病的新平台。合成生物学在这些生物实体的工程化中起着关键作用。因此,在本综述中,简要总结了合成生物学在设计和创建基因工程新型生物材料,特别是细菌方面在诊断和靶向递送中的作用。主要重点是提供有关基于工程细菌的疗法的最新进展的知识,特别是在癌症、炎症性肠病和感染的治疗方面。微生物,特别是益生菌,已被工程化用于合成生物疗法。此外,这些可编程细菌被设计用于感知输入信号并以多方面的治疗输出对疾病变化的环境做出反应。这些ELMs将为再生药物的合成开辟一条新途径,因为它们释放的治疗剂可提供全身作用较低的药物递送。最后,讨论了该领域面临的挑战以及需要突破的未来方向。总之,目的是介绍过去5年基于工程细菌的疗法在研究和生物医学应用方面的最新进展,作为一种治疗无法控制的疾病的新方法。